Ultime notizie per National Healthcare (AMEX:NHC) Azioni

National Healthcare

National Healthcare Corp Provides long-term care facilities. Its principal business includes the operation of skilled nursing facilities, assisted living facilities, independent living facilities, and home care programs. The company's activities include providing sub-acute and post-acute skilled nursing care, intermediate nursing care, rehabilitative care, memory and Alzheimer's care, senior living services, and home health care services. In addition, the company also provides management services, accounting, and financial services, as well as insurance services to third-party operators of healthcare facilities. Its reportable segments include Inpatient services, and Home care hospice services. Generating, a majority of its revenue from Inpatient services.

National HealthCare Corporation Common Stock

National Healthcare Corp

NHC COMMUNS INC by NHC Communications Inc.

NHC Communications Inc

NIHON CHOUZAI CO LTD ORD by Nihon Chouzai Co., Ltd.

Nihon Chouzai Co Ltd

National Healthcare (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NHC#AMEX">NHC</a>) reported quarterly earnings of $1.00 per share. This is a 12.36 percent increase over earnings of $0.89 per share from the same period last year. The company reported $300.66 million in sales this quarter. This is a 6.40 percent increase over sales of $282.58 million the same period last year.

Earnings

News

National Healthcare Q2 Adj $1.00 Up From $0.89 YoY, Sales $300.66M Up From $282.58M YoY

National HealthCare Corporation To Acquire White Oak Senior Living Portfolio In North And South Carolina, Including Long-Term Care Pharmacy; Transaction Expected To Close In Q3 2024; Financial Terms Not Disclosed

National Healthcare (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NHC#AMEX">NHC</a>) reported quarterly Adj&nbsp;earnings of $0.97 per share. This is a 22.78 percent increase over earnings of $0.79 per share from the same period last year. The company reported $297.18 million in sales this quarter. This is a 10.24 percent increase over sales of $269.56 million the same period last year.

National Healthcare Q1 Adj EPS $0.97 Up From $0.79 YoY, Sales $297.18M Up From $269.56M YoY

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nhccare.com&amp;esheet=53983317&amp;newsitemid=20240509812071&amp;lan=en-US&amp;anchor=National+HealthCare+Corporation&amp;index=1&amp;md5=d9968a2849d838dc5cf6cd0ccd932a9f">National HealthCare Corporation</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHC#NYSE">NHC</a>), the nation's oldest publicly traded long-term health care company, announced today that it will pay a quarterly dividend of 61 cents per common share to shareholders of record on June 28, 2024 and payable on August 1, 2024. This represents a 3.4% increase over last quarter's regular common dividend.

Dividends

NHC Increase Quarterly Dividend From $0.59 To $0.61 Per Share

National Healthcare (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NHC#AMEX">NHC</a>) reported quarterly earnings of $1.03 per share. This is a 43.06 percent increase over earnings of $0.72 per share from the same period last year. The company reported $300.91 million in sales this quarter. This is a 13.74 percent increase over sales of $264.55 million the same period last year.

National Healthcare Q4 Adj. EPS $1.03 Up From $0.72 YoY, Sales $300.91M Up From $264.55M YoY

U.S. stocks traded lower, with the Dow Jones index falling more than 100 points on Monday.
Shares of Science Applications International Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/saic#NYSE">SAIC</a>) surged during Monday&rsquo;s session after the company reported third-quarter financial results and raised FY24 <a href="https://www.benzinga.com/news/earnings/23/12/36066719/why-it-company-saics-shares-are-surging-today">guidance above estimates</a>.
SAIC reported a 1% revenue decline Y/Y in Q3 FY24 to $1.895 billion, beating the consensus of $1.790 billion. Adjusted EPS of $2.27 beat the consensus of $1.69.
SAIC raised revenue guidance to $7.325 billion - $7.350 billion (prior $7.20 billion - $7.25 billion). The company increased adjusted EPS guidance to $7.70 - $7.90 (prior $7.20 - $7.40).
Science Applications International shares rose 6.9% to $128.20 on Monday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Hawaiian Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ha#NASDAQ">HA</a>) shares jumped 187% to $14.03 after Alaska Air Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alk#NYSE">ALK</a>) announced plans to acquire the company in a deal worth $1.9 billion.</li>
<li>XBP Europe Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xbp#NASDAQ">XBP</a>) rose 39.5% to $33.28.</li>
<li>Beyond Meat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bynd#NASDAQ">BYND</a>) shares gained 23.6% to $9.36.</li>
<li>B. Riley Financial, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rily#NASDAQ">RILY</a>) jumped 19.4% to $24.09. Bryant R. Riley reported sale of most of its stake in Arena Group to Arena.</li>
<li>Biomea Fusion, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmea#NASDAQ">BMEA</a>) climbed 18.8% to $19.82.</li>
<li>Wallbox N.V. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wbx#NYSE">WBX</a>) gained 16.3% to $1.8150 after Generac announced it made a minority investment in the company.</li>
<li>CleanSpark, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clsk#NASDAQ">CLSK</a>) surged 16.1% to $8.87amid a weekend increase in the price of Bitcoin.</li>
<li>Newegg Commerce, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/negg#NASDAQ">NEGG</a>) shares rose 15.5% to $2.08.</li>
<li>Carvana Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cvna#NYSE">CVNA</a>) rose 15.3% to $40.56 after JP Morgan upgraded the stock from Underweight to Neutral and raised its price target from $25 to $40.</li>
<li>Terns Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tern#NASDAQ">TERN</a>) surged 15.3% to $6.02.</li>
<li>Consensus Cloud Solutions, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ccsi#NASDAQ">CCSI</a>) rose 12.6% to $21.55.</li>
<li>TeraWulf Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wulf#NASDAQ">WULF</a>) gained 12.5% to $1.54 amid a weekend surge in the price of Bitcoin.</li>
<li>Calavo Growers, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvgw#NASDAQ">CVGW</a>) jumped 11.9% to $25.67.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mara#NASDAQ">MARA</a>) surged 11.4% to $15.26 amid a weekend surge in the price of Bitcoin.</li>
<li>Riot Platforms, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/riot#NASDAQ">RIOT</a>) gained 11.1% to $15.30 amid a weekend surge in the price of Bitcoin.</li>
<li>National HealthCare Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nhc#NYSE">NHC</a>) rose 10.3% to $85.56.</li>
<li>Spotify Technology S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spot#NYSE">SPOT</a>) climbed 8.6% to $196.07. Spotify CEO Daniel Ek announced significant organizational changes, including reducing the company&#39;s headcount by approximately 17%.</li>
<li>Fluence Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flnc#NASDAQ">FLNC</a>) gained 7% to $27.57. Roth MKM upgraded Fluence Energy from Neutral to Buy and raised the price target from $27 to $31.</li>
<li>IDEXX Laboratories, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idxx#NASDAQ">IDXX</a>) gained 6.4% to $513.47.</li>
<li>GameStop Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gme#NYSE">GME</a>) climbed 6% to $16.19.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) rose 6% to $558.56 amid a weekend surge in the price of Bitcoin.</li>
<li>Coinbase Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coin#NASDAQ">COIN</a>) gained 5.5% to $141.14 amid a weekend surge in the price of Bitcoin.</li>
<li>Uber Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uber#NYSE">UBER</a>) climbed 5% to $60.22 after an announcement that the company would join the S&amp;P 500 index.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/12/36069416/over-2m-bet-on-this-industrial-stock-check-out-these-4-penny-stocks-insiders-are-aggress"> Over $2M Bet On This Industrial Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying</a>

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

BMEA

BYND

CCSI

CLSK

COIN

CVGW

CVNA

FLNC

IDXX

MARA

MSTR

NEGG

RILY

RIOT

SAIC

SPOT

TERN

UBER

WULF

SAIC Reports Q3 Results, Joins Uber, Wallbox And Other Big Stocks Moving Higher On Monday

Robert G Adams, Board Member at National Healthcare (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NHC#AMEX">NHC</a>), reported a large insider buy on September 14, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001047335/000143774923025905//Archives/edgar/data/1047335/000143774923025905/0001437749-23-025905-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that Adams purchased 2,000 shares of National Healthcare. The total transaction amounted to $133,923. 
National Healthcare shares are trading down 0.77% at $67.32 at the time of this writing on Friday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001047335">Check Out The Full List Of National Healthcare's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

National Healthcare Board Member Trades $133K In Company Stock

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi"> RSI is above 70.</a>
Here&rsquo;s the latest list of major overbought players in this sector.
<h3>Capricor Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/capr#NASDAQ">CAPR</a>)</h3>
<ul>
<li>The company posted better-than-expected quarterly results. &ldquo;In the second quarter of 2023 we presented positive two-year data from our ongoing HOPE-2 open label extension (OLE) study, which we believe further supports our rapidly advancing late-stage clinical development program for CAP-1002 in patients with Duchenne Muscular Dystrophy (DMD),&rdquo; said Linda Marb&aacute;n, Ph.D., Capricor&rsquo;s chief executive officer. The company&rsquo;s stock has a <a href="https://www.benzinga.com/quote/CAPR">52-week high of $8.11. </a>.</li>
<li>RSI Value: 71.52</li>
<li>CAPR Price Action: Shares of Capricor Therapeutics fell 4.9% to close at $7.34 on Monday.</li>
</ul>
<h3>Praxis Precision Medicines, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prax#NASDAQ">PRAX</a>)</h3>
<ul>
<li>Praxis Precision Medicine posted a narrower second-quarter loss. &ldquo;Our four clinical-stage programs continue to make great progress, and we are excited to be advancing ulixacaltamide into Phase 3,&rdquo; said Marcio Souza, president and chief executive officer of Praxis. The company&rsquo;s <a href="https://www.benzinga.com/quote/PRAX"> stock has a 52-week high </a> of $5.25.</li>
<li>RSI Value: 71.29</li>
<li>PRAX Price Action: Shares of Praxis Precision Medicines fell 3.5% to close at $1.40 on Tuesday.</li>
</ul>
<h3>National HealthCare Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nhc#NYSE">NHC</a>)</h3>
<ul>
<li>For the quarter ended June 30, 2023, the reported GAAP net income attributable to NHC was $16,281,000, up from $3,203,000 for the year-ago period. The company has a <a href="https://www.benzinga.com/quote/NHC"> 52-week high </a> of $70.78.</li>
<li>RSI Value: 74.30</li>
<li>NHC Price Action: Shares of National HealthCare fell 0.7% to close at $68.56 on Tuesday.</li>
</ul>
<h3>Regeneron Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/regn#NASDAQ">REGN</a>)</h3>
<ul>
<li>Regeneron Pharmaceuticals Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/regn#NASDAQ">REGN</a>) was awarded a government contract valued at up to $326 million. &quot;Although COVID-19 has moved to an endemic stage, many people &ndash; including those with immunocompromising conditions &ndash; continue to face exposure that impacts their everyday life and could cause serious health consequences,&quot; said Leonard Schleifer, board co-chair, president and CEO of Regeneron. The company&rsquo;s 52-week high is $10.25.</li>
<li>RSI Value: 76.55</li>
<li>REGN Price Action: Shares of Regeneron Pharmaceuticals fell 0.4% to close at $840.63 on Monday.</li>
</ul>
<h3>Dr. Reddy&#39;s Laboratories Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rdy#NYSE">RDY</a>)</h3>
<ul>
<li>Dr Reddy&#39;s Laboratories reported better-than-expected first-quarter financial results. Co-Chairman &amp; MD, G V Prasad said, &quot;We delivered strong sales growth and witnessed robust margin expansion in Q1FY24 driven by market share gains &amp; new product momentum in our US generics business and superior performance in Russia.&quot; The company <a href="https://www.benzinga.com/quote/RDY"> has a 52-week high </a> of $72.13.</li>
<li>RSI Value: 75.61</li>
<li>RDY Price Action: Shares of Dr. Reddy&#39;s Laboratories fell 0.4% to settle at $71.47 on Tuesday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/earnings/23/08/33998119/advance-auto-parts-likely-to-post-sharp-decline-in-q2-earnings-heres-a-look-at-recent-price-target-"> Advance Auto Parts Likely To Post Sharp Decline In Q2 Earnings; Here&#39;s A Look At Recent Price Target Changes By The Most Accurate Analysts</a>

Short Ideas

Pre-Market Outlook

CAPR

PRAX

REGN

Top 5 Health Care Stocks That May Fall Off A Cliff

Although US stocks closed slightly higher on Monday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#39;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Black Diamond Therapeutics </h3>
<ul>
<li>The Trade: Black Diamond Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bdtx#NASDAQ">BDTX</a>) 10% owner BB Biotech AG <a href="https://www.benzinga.com/quote/BDTX/analyst-ratings"> acquired a total of 1,000,000 shares </a> an average price of $5.00. To acquire these shares, it cost around $5 million.</li>
<li>What&rsquo;s Happening: Stifel upgraded Black Diamond Therapeutics from Hold to Buy and raised the price target from $2 to $10.</li>
<li>What Black Diamond Therapeutics Does: Black Diamond Therapeutics Inc is a precision oncology medicine company.</li>
</ul>
<h3>National HealthCare </h3>
<ul>
<li>The Trade: National HealthCare Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nhc#NYSE">NHC</a>) Director Richard F. Laroche Jr. acquired a total of 2,100 shares at an average price of $61.40. To acquire these shares, it cost around $128,944.</li>
<li>What&rsquo;s Happening: - -National HealthCare reported net operating revenues and grant income for the quarter ended March 31, 2023 totaled $269,563,000, up from $278,983,000 for the quarter ended March 31, 2022.</li>
<li>What National HealthCare Does: National Healthcare Corp Provides long-term care facilities. Its principal business includes the operation of skilled nursing facilities, assisted living facilities, independent living facilities, and home care programs.</li>
</ul>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
<h3>Healthcare Services Group </h3>
<ul>
<li>The Trade: Healthcare Services Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hcsg#NASDAQ">HCSG</a>) Director Kurt Simmons Jr <a href="https://www.benzinga.com/sec/insider-trades/"> bought a total of 1,005 shares </a> at an average price of $14.93. To acquire these shares, it cost around $15,005.</li>
<li>What&rsquo;s Happening: Healthcare Services Group reported revenue of $417.2 million for the three months ended March 31, 2023.</li>
<li>What Healthcare Services Group Does: Healthcare Services Group Inc is a provider of housekeeping and facility management services to the healthcare industry.</li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/earnings/23/07/33111009/investor-sentiment-declines-ahead-of-fed-minutes"> Investor Sentiment Declines Ahead Of Fed Minutes </a>

Long Ideas

BDTX

HCSG

$5M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying

Ernest G. Burgess III, Board Member at National Healthcare (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NHC#AMEX">NHC</a>), reported a large insider buy on May 17, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001047335/000143774923014974//Archives/edgar/data/1047335/000143774923014974/0001437749-23-014974-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that III purchased 2,300 shares of National Healthcare. The total transaction amounted to $135,350. 
National Healthcare shares are trading up 1.33% at $59.46 at the time of this writing on Thursday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001047335">Check Out The Full List Of National Healthcare's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Board Member At This Health Care Company Buys $135K of Stock

<h1>&nbsp;</h1>
On Monday, 36 companies set new 52-week lows.
<h2>Noteworthy Mentions In Today&#39;s 52-Week Lows:</h2>
<ul>
<li>The largest company by market cap to hit a new 52-week low was Sirius XM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>).</li>
<li>The smallest company by market cap to set a new 52-week low was Altamira Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTO#NASDAQ">CYTO</a>).</li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) saw the most significant move of the companies, as shares traded down 871.52% to reach its new 52-week low.</li>
<li>VEON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) shares rebounded the highest, with shares trading up 0.0%, bouncing back after reaching its new 52-week low.</li>
</ul>
Stocks dropping to new 52-week lows on Monday:
<ul>
<li>Sirius XM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) shares fell to $4.20 on Monday, setting a new 52-week low with a shift of down 0.35%.</li>
<li>Centrais Eletricas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBR#NYSE">EBR</a>) shares hit a yearly low of $6.26. The stock was down 1.1% on the session.</li>
<li>Cosan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSAN#NYSE">CSAN</a>) stock achieved a new 52-week low on Monday morning, hitting $11.14 and moving up 0.09%.</li>
<li>Equity Commonwealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQC#NYSE">EQC</a>) shares were down 0.12% for the day, having made a 52-week low of $20.53.</li>
<li>VEON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) stock broke to a new 52-week low of $0.68 on Monday. Shares of the company traded 0.0% (flat).</li>
<li>National Healthcare (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NHC#AMEX">NHC</a>) shares hit a yearly low of $54.76. The stock was up 0.16% on the session.</li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) stock hit a yearly low of $5.77. The stock was down 52.03% for the day.</li>
<li>Greystone Housing Impact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHI#NYSE">GHI</a>) shares reached a new 52-week low of $17.05 on Monday morning, moving down 2.4%.</li>
<li>Guaranty Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTY#NASDAQ">GNTY</a>) shares set a new 52-week low of $30.51. The stock traded down 0.88%.</li>
<li>Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) shares set a new 52-week low of $19.77. The stock traded down 4.73%.</li>
<li>Bright Health Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHG#NYSE">BHG</a>) shares reached a new 52-week low of $0.43 on Monday morning, moving down 0.04%.</li>
<li>Amneal Pharmaceuticals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NYSE">AMRX</a>) shares moved down 3.65% on Monday to hit a new 52-week low of $1.81, drifting down 3.65%.</li>
<li>enCore Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EU#AMEX">EU</a>) shares fell to $2.20 on Monday, setting a new 52-week low with a shift of down 1.32%.</li>
<li>Franklin Street Props (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FSP#AMEX">FSP</a>) stock hit $2.19 on Monday morning, setting a new 52-week low for a change of down 3.31%.</li>
<li>Kinnate Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNTE#NASDAQ">KNTE</a>) shares were down 4.7% for the day, having made a 52-week low of $4.71.</li>
<li>Aadi Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AADI#NASDAQ">AADI</a>) stock achieved a new 52-week low on Monday morning, hitting $8.89 and moving down 3.97%.</li>
<li>Azure Power Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZRE#NYSE">AZRE</a>) shares were down 12.46% for the day, having made a 52-week low of $2.66.</li>
<li>Universal Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UEIC#NASDAQ">UEIC</a>) stock drifted down 2.51% on Monday morning to hit a new 52-week low of $11.53.</li>
<li>Cepton (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPTN#NASDAQ">CPTN</a>) shares set a new 52-week low of $0.86. The stock traded down 7.63%.</li>
<li>Intercure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCR#NASDAQ">INCR</a>) shares were down 6.32% for the day, having made a 52-week low of $2.37.</li>
<li>Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) shares reached a new 52-week low of $5.14 on Monday morning, moving down 1.7%.</li>
<li>AERWINS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWIN#NASDAQ">AWIN</a>) stock set a new 52-week low of $1.00 on Monday, moving down 12.5%.</li>
<li>Evaxion Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) stock broke to a new 52-week low of $1.18 on Monday. Shares of the company traded down 6.79%.</li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) shares hit a yearly low of $0.57. The stock was up 871.52% on the session.</li>
<li>CN Energy Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>) shares reached a new 52-week low of $0.28 on Monday morning, moving down 1.99%.</li>
<li>Inpixon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INPX#NASDAQ">INPX</a>) stock hit a yearly low of $0.81. The stock was down 7.34% for the day.</li>
<li>Jupiter Wellness (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUPW#NASDAQ">JUPW</a>) stock hit a yearly low of $0.41. The stock was down 1.7% for the day.</li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) stock dropped to a yearly low on Monday of $3.08. Shares traded down 12.25%.</li>
<li>Rubius Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUBY#NASDAQ">RUBY</a>) stock set a new 52-week low of $0.09 on Monday, moving down 22.26%.</li>
<li>Panbela Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBLA#NASDAQ">PBLA</a>) shares made a new 52-week low of $0.89 on Monday. The stock was down 2.42% for the day.</li>
<li>Petros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock broke to a new 52-week low of $1.71 on Monday. Shares of the company traded up 3.26%.</li>
<li>Kalera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KAL#NASDAQ">KAL</a>) shares reached a new 52-week low of $4.10 on Monday morning, moving down 2.79%.</li>
<li>Altamira Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTO#NASDAQ">CYTO</a>) shares hit a yearly low of $2.03. The stock was down 13.11% on the session.</li>
</ul>
Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. <a href="https://pro.benzinga.com/?afmc=2a&amp;utm_source=benzinga.com&amp;utm_medium=web&amp;utm_campaign=premium_products">Click here to learn more</a>.

Options

AADI

ACRS

AMRX

AWIN

AZRE

CNEY

CPHI

CPTN

CSAN

CYTO

EVAX

GNTY

INCR

INPX

JUPW

KNTE

PBLA

PTPI

RUBY

SIRI

SLDB

SRDX

UEIC

VEON

Stocks That Hit 52-Week Lows On Monday

National Healthcare (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NHC#AMEX">NHC</a>) reported quarterly earnings of $0.72 per share. This is a 29.41 percent decrease over earnings of $1.02 per share from the same period last year. The company reported $264.55 million in sales this quarter. This is a 6.66 percent decrease over sales of $283.43 million the same period last year.

National Healthcare Q4 Adj EPS $0.72 Down From $1.02 YoY, Sales $264.55M Down From $283.43M YoY

<h1>&nbsp;</h1>
On Thursday, 63 companies set new 52-week lows.
<h2>Points of Interest From Today&#39;s 52-Week Lows:</h2>
<ul>
<li>Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) was the largest company by market cap to set a new 52-week low.</li>
<li>The company with the smallest market cap to set a new 52-week low was Novo Integrated Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>).</li>
<li>Silvergate Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SI#NYSE">SI</a>) was the biggest loser of the morning session, as it dropped 45.88% to reach its new 52-week low.</li>
<li>Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low.</li>
</ul>
On Thursday, the following stocks set new 52-week lows:
<ul>
<li>Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) shares were down 2.69% for the day, having made a 52-week low of $133.69.</li>
<li>TC Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRP#NYSE">TRP</a>) stock set a new 52-week low of $38.58 on Thursday, moving down 1.26%.</li>
<li>CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) shares moved down 8.03% on Thursday to hit a new 52-week low of $94.63, drifting down 8.03%.</li>
<li>Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>) shares reached a new 52-week low of $57.76 on Thursday morning, moving down 2.51%.</li>
<li>Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) stock hit a yearly low of $65.46. The stock was down 3.61% for the day.</li>
<li>Extra Space Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>) shares were down 1.88% for the day, having made a 52-week low of $140.65.</li>
<li>Invitation Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVH#NYSE">INVH</a>) stock hit a new 52-week low of $28.73. The stock was down 2.49% on the session.</li>
<li>Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) shares made a new 52-week low of $105.67 on Thursday. The stock was down 4.13% for the day.</li>
<li>Life Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSI#NYSE">LSI</a>) stock dropped to a yearly low on Thursday of $94.45. Shares traded down 1.28%.</li>
<li>XP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>) stock broke to a new 52-week low of $13.76 on Thursday. Shares of the company traded down 3.16%.</li>
<li>Signature Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBNY#NASDAQ">SBNY</a>) stock hit $109.95 on Thursday morning, setting a new 52-week low for a change of down 3.02%.</li>
<li>GameStop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares reached a new 52-week low of $16.41 on Thursday morning, moving down 4.42%.</li>
<li>Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) stock broke to a new 52-week low of $22.32 on Thursday. Shares of the company traded down 2.61%.</li>
<li>Braskem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAK#NYSE">BAK</a>) stock hit a yearly low of $8.23. The stock was up 0.85% for the day.</li>
<li>Douglas Emmett (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEI#NYSE">DEI</a>) stock drifted down 2.95% on Thursday morning to hit a new 52-week low of $14.97.</li>
<li>Asana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) stock hit a yearly low of $12.28. The stock was down 8.02% for the day.</li>
<li>Independent Bank Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBTX#NASDAQ">IBTX</a>) stock drifted down 1.41% on Thursday morning to hit a new 52-week low of $56.37.</li>
<li>Appian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) stock hit $30.55 on Thursday morning, setting a new 52-week low for a change of down 3.01%.</li>
<li>Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) shares reached a new 52-week low of $18.07 on Thursday morning, moving down 4.96%.</li>
<li>Xenia Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XHR#NYSE">XHR</a>) stock dropped to a yearly low on Thursday of $12.48. Shares traded down 0.85%.</li>
<li>Hudson Pacific Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>) shares hit a yearly low of $9.29. The stock was down 2.58% on the session.</li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) shares hit a yearly low of $2.03. The stock was down 0.97% on the session.</li>
<li>National Healthcare (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NHC#AMEX">NHC</a>) shares set a new 52-week low of $56.98. The stock traded down 1.47%.</li>
<li>Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) shares were down 1.38% for the day, having made a 52-week low of $5.41.</li>
<li>Laredo Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPI#NYSE">LPI</a>) shares made a new 52-week low of $46.62 on Thursday. The stock was up 0.93% for the day.</li>
<li>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) stock dropped to a yearly low on Thursday of $33.20. Shares traded down 9.65%.</li>
<li>MultiPlan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>) stock broke to a new 52-week low of $0.98 on Thursday. Shares of the company traded down 4.13%.</li>
<li>First Mid Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMBH#NASDAQ">FMBH</a>) shares reached a new 52-week low of $31.40 on Thursday morning, moving down 1.72%.</li>
<li>Designer Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>) stock hit $9.07 on Thursday morning, setting a new 52-week low for a change of down 1.06%.</li>
<li>CrossFirst Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFB#NASDAQ">CFB</a>) shares reached a new 52-week low of $11.79 on Thursday morning, moving down 3.86%.</li>
<li>Luther Burbank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBC#NASDAQ">LBC</a>) shares moved down 1.19% on Thursday to hit a new 52-week low of $10.72, drifting down 1.19%.</li>
<li>Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>) shares set a new yearly low of $10.83 this morning. The stock was 0.0% (flat) on the session.</li>
<li>Viad (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVI#NYSE">VVI</a>) stock hit a new 52-week low of $23.56. The stock was down 2.0% on the session.</li>
<li>Orion Office REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONL#NYSE">ONL</a>) stock hit $8.20 on Thursday morning, setting a new 52-week low for a change of down 0.42%.</li>
<li>Solid Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDP#NASDAQ">SLDP</a>) shares reached a new 52-week low of $2.12 on Thursday morning, moving down 4.24%.</li>
<li>Silvergate Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SI#NYSE">SI</a>) shares reached a new 52-week low of $11.32 on Thursday morning, moving down 45.88%.</li>
<li>Intrepid Potash (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPI#NYSE">IPI</a>) shares moved up 0.54% on Thursday to hit a new 52-week low of $27.23, drifting up 0.54%.</li>
<li>Seer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEER#NASDAQ">SEER</a>) shares set a new yearly low of $4.23 this morning. The stock was down 2.41% on the session.</li>
<li>Charge Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGE#NASDAQ">CRGE</a>) shares reached a new 52-week low of $1.11 on Thursday morning, moving down 3.88%.</li>
<li>Bed Bath &amp; Beyond (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBBY#NASDAQ">BBBY</a>) shares hit a yearly low of $1.83. The stock was down 23.69% on the session.</li>
<li>Lifecore Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) stock broke to a new 52-week low of $6.15 on Thursday. Shares of the company traded down 1.72%.</li>
<li>Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) shares hit a yearly low of $5.50. The stock was down 10.53% on the session.</li>
<li>LL Flooring Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LL#NYSE">LL</a>) shares set a new yearly low of $5.14 this morning. The stock was down 2.4% on the session.</li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) stock hit a yearly low of $1.01. The stock was down 7.36% for the day.</li>
<li>D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) shares set a new 52-week low of $1.19. The stock traded down 0.78%.</li>
<li>Xeris Biopharma Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XERS#NASDAQ">XERS</a>) stock drifted down 4.13% on Thursday morning to hit a new 52-week low of $0.97.</li>
<li>Aemetis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMTX#NASDAQ">AMTX</a>) shares fell to $3.70 on Thursday, setting a new 52-week low with a shift of down 3.55%.</li>
<li>Altisource Portfolio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPS#NASDAQ">ASPS</a>) stock dropped to a yearly low on Thursday of $7.91. Shares traded down 4.62%.</li>
<li>Euroseas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESEA#NASDAQ">ESEA</a>) shares fell to $17.65 on Thursday, setting a new 52-week low with a shift of down 1.62%.</li>
<li>Yellow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YELL#NASDAQ">YELL</a>) shares set a new yearly low of $2.40 this morning. The stock was down 4.55% on the session.</li>
<li>Sono Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEV#NASDAQ">SEV</a>) shares fell to $0.85 on Thursday, setting a new 52-week low with a shift of down 4.84%.</li>
<li>Hydrofarm Holdings Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYFM#NASDAQ">HYFM</a>) stock broke to a new 52-week low of $1.42 on Thursday. Shares of the company traded down 5.23%.</li>
<li>Ondas Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) stock hit a yearly low of $1.42. The stock was down 4.3% for the day.</li>
<li>RiverNorth Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSF#NYSE">RSF</a>) stock hit a new 52-week low of $16.15. The stock was down 3.07% on the session.</li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTBC#NASDAQ">MTBC</a>) stock achieved a new 52-week low on Thursday morning, hitting $2.50 and moving down 3.75%.</li>
<li>Camber Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CEI#AMEX">CEI</a>) stock hit a yearly low of $1.78. The stock was down 4.25% for the day.</li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) shares were down 4.27% for the day, having made a 52-week low of $2.21.</li>
</ul>
Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. <a href="https://pro.benzinga.com/?afmc=2a&amp;utm_source=benzinga.com&amp;utm_medium=web&amp;utm_campaign=premium_products">Click here to learn more</a>.

ALLO

AMTX

APPN

ASAN

ASPS

BBBY

BIOR

CELU

CRGE

CRGY

CRWD

DDOG

ESEA

FMBH

HYFM

IBTX

INVH

JAMF

LFCR

MPLN

MTBC

NVOS

ONDS

PANW

QBTS

RiverNorth Marketplace Lending Corporation Common Stock

SBNY

SEER

SLDP

TDOC

VERA

XERS

YELL

Stocks That Hit 52-Week Lows On Thursday

National Healthcare (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NHC#AMEX">NHC</a>) reported quarterly earnings of $0.50 per share. This is a 47.92 percent decrease over earnings of $0.96 per share from the same period last year. The company reported $270.84 million in sales this quarter. This is a 2.13 percent decrease over sales of $276.74 million the same period last year.

National Healthcare Q3 EPS $0.50 Down From $0.96 YoY, Sales $270.84M Down From $276.74M YoY

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nhccare.com&amp;esheet=52805901&amp;newsitemid=20220808005826&amp;lan=en-US&amp;anchor=National+HealthCare+Corporation&amp;index=1&amp;md5=b96d67df0dce73a70ab000e731b360a6">National HealthCare Corporation</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHC#NYSE">NHC</a>), announces that its Board of Directors, at a regularly scheduled meeting, has authorized a new stock repurchase program. The program will allow for repurchases of up to&nbsp;$25 million&nbsp;of its common stock. The new stock repurchase plan will begin August 11, 2022 and will expire on August 10, 2023. The stock repurchase plan replaces the stock repurchase plan previously approved by the Board of Directors on August 8, 2019, which expired on August 31, 2020.
Under the stock repurchase program, the Company may repurchase its common stock from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions and other considerations. The Company&#39;s repurchases may be executed using open market purchases, privately negotiated agreements or other transactions. The Company intends to fund repurchases under the new stock repurchase program from cash on hand, available borrowings or proceeds from potential debt or other capital market sources. The stock repurchase program may be suspended or discontinued at any time without prior notice. The Company will provide an update regarding any purchases made pursuant to the stock repurchase program each time it reports its results of operations.

Buybacks

NHC Announces $25 Million Stock Repurchase Program

National Healthcare Q2 EPS $0.46 vs $0.98 YoY

<h3>What Defines a Value Stock?</h3>
A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued. 
<h2>Below is a list of notable value stocks in the healthcare sector:</h2>
<ol>
<li>Tilray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) - P/E: 9.43</li>
<li>National Healthcare (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NHC#AMEX">NHC</a>) - P/E: 8.11</li>
<li>Sensus Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) - P/E: 6.22</li>
<li>Achilles Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHL#NASDAQ">ACHL</a>) - P/E: 0.45</li>
<li>Innoviva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVA#NASDAQ">INVA</a>) - P/E: 6.62</li>
</ol>
Tilray has been featured as a value stock. Tilray's Q3 EPS sits at $0.03, which has not changed since last quarter (Q2). Most recently, National Healthcare reported earnings per share at $0.91, whereas in Q4 earnings per share sat at $1.02. Most recently, the company reported a dividend yield of 3.23%, which has decreased by 0.18% from last quarter's yield of 3.41%.
Sensus Healthcare saw a decrease in earnings per share from 0.32 in Q4 to $0.2 now. Achilles Therapeutics looks to be undervalued. It possesses an EPS of $-0.45, which has not changed since last quarter (Q4). Most recently, Innoviva reported earnings per share at $0.39, whereas in Q4 earnings per share sat at $0.14. 
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

ACHL

INVA

SRTS

TLRY

5 Value Stocks To Watch In The Healthcare Sector

Is the United States heading toward a recession?
This has been the looming question on the minds of Americans since inflation topped at 8.5% in March, matched with other indicators such as&nbsp;rising interest rates and the bond market&rsquo;s inverted yield curve.
Top economists are split on the inevitability of a recession.&nbsp;Former&nbsp;Goldman Sachs Group Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gs#NYSE">GS</a>)&nbsp;CEO Lloyd Blankfein <a href="https://www.youtube.com/watch?v=fDfsV9A4Q1M">said over the weekend</a>, &ldquo;It&rsquo;s certainly a very, very high-risk factor,&rdquo; but believes that the Fed is responding well to the risk.
Moody&rsquo;s Corporation&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mco#NYSE">MCO</a>) chief economist Mark Zandi <a href="https://fortune.com/2022/04/19/will-economy-enter-recession-odds-mark-zandi-biden/">predicted </a>a 35% probability that America will enter a recession in the next two years. Twitter Inc.&#39;s&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/twtr#NYSE">TWTR</a>)&nbsp;most-loved Elon Musk <a href="https://twitter.com/elonmusk/status/1476619907076923398?lang=en">predicted&nbsp;a recession</a> as early as the summer of 2022.
Conflicting outlooks aside, it is essential to look at the facts and what has historically preceded a recession.
The yield curve inverted on March 29 for the first time since 2019. This occurs when the short-term U.S. treasury is paying a higher interest rate than long-term U.S. treasuries. More than that, Fed Chair Jerome Powell indicated a 50 basis point increase, up from the traditional 0.25% at the last FOMC (Federal Open Market Committee) meeting.
The known definition of a recession is a period of temporary economic decline during which trade and industrial activity are reduced, generally identified by a fall in GDP in two successive quarters. <a href="https://www.bea.gov/news/2022/gross-domestic-product-first-quarter-2022-advance-estimate#:~:text=Real%20gross%20domestic%20product%20(GDP,real%20GDP%20increased%206.9%20percent.">According to the Bureau of Economic analysis</a>, the GDP decreased at an annual rate of 1.4%, down from 6.9% in the fourth quarter of 2021.
While the macro outlook is pessimistic at best, it is critical to understand the broader market trends that indicate where money moves, such as&nbsp;the economic cycle and sector rotation.
It is&nbsp;known that a recession is a natural part of a growing economy and&nbsp;as part of the economic cycle. The cycle can be simply defined as when the economy moves from a growth stage to a recession and back to growth. This is probably the most influential force on the broader markets because it directly relates to stock prices vis-a-vis company profits.
The stock market&#39;s relationship with the economic cycle lies in the various sectors that make up the markets, which are sensitive to different stages of the cycle.
Are you confused yet? This should make it easy.
Some sectors will outperform when the economy is growing (Industrials, Consumer names, Real Estate) and others when the economy is in a recession (Healthcare, Food, Consumer Staples, Utilities)
This is known as sector rotation or the way investors move money during the various stages of the economic cycle.
When the economy moves toward a recession, investors usually rotate into sectors that are less sensitive to the economic cycle, such as&nbsp;Consumer Staples and Utilities; these are known as defensive sectors because they can offer a relative level of protection during an economic downturn.
Some of those defensive names include:
Coca-Cola Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ko#NYSE">KO</a>) 
Albertsons Companies Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aci#NYSE">ACI</a>) 
Altria Group Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mo#NYSE">MO</a>) 
NRG Energy Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nrg#NYSE">NRG</a>) 
PG&amp;E Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pcg#NYSE">PCG</a>) 
Clearway Energy Inc&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cwen#NYSE">CWEN</a>) 
National HealthCare Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nhc#NYSE">NHC</a>) 
HealthStream, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hstm#NASDAQ">HSTM</a>) 
Regencell Bioscience Holdings Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rgc#NASDAQ">RGC</a>)
On the opposite end, when emerging from a recession, investors rotate into highly sensitive names to the cycle, such as&nbsp;Industrials and Consumer cyclicals.
Read also:&nbsp;<a href="http://NYSE Or NASDAQ? Here's Why Stocks Get Listed">NYSE Or NASDAQ? Here&#39;s Why Stocks Get Listed&nbsp;There</a>
Some of those names include:
Caterpillar Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cat#NYSE">CAT</a>) 
Johnson &amp; Johnson (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>) 
Ecolab Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ecl#NYSE">ECL</a>) 
Chevron Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cvx#NYSE">CVX</a>) 
Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) 
JPMorgan Chase &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jpm#NYSE">JPM</a>) 
Boeing Co&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ba#NYSE">BA</a>) 
Mastercard Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ma#NYSE">MA</a>)

Entertainment

Education

General

CWEN

HSTM

TSLA

TWTR

Sector Rotation And 9 Stocks To Watch During A Recession

When we enter a period of economic uncertainty, the phrase &quot;recession-proof stocks&quot; is tossed about, but really the only certainty is that recession-proof stocks do not exist.
On the other hand, recession-resistant companies&nbsp;are what a savvy investor searches for during the absence of a bull market, as we are now.
Historically, cyclical sectors such as&nbsp;financial&nbsp;and consumer directories have outperformed during bull markets. These equities are frequently susceptible to interest rates and economic growth, so they perform worse than others during a bear market or imminent recession.
Consumer preferences shift from optional and luxury purchases to essential home products and services during a recession as individuals are more concerned with their bottom line.
During uncertain periods such as&nbsp;this, the smart money rotates into recession-resistant or defensive sectors like Consumer Staples, Utilities and Health Care, all of which historically perform well during a recession.
Energy (+49.17%) is the sector with the most significant returns this year, owing to rising oil prices, supply-chain concerns, and demand for gas, energy equipment, and services while the war in Ukraine continues.
This bear market is different. Year-to-date, the returns for the following sectors are: 
Consumer Staples: -0.62% 
Utilities: +0.73% 
Health Care: -8.1%
On the surface, these sectors could look like uncertain investments, bur peeking into them tells a different story and provides investment ideas.
Consumer Staples: 
Beverages: +2.21%
<ul>
<li>Coca-Cola Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ko#NYSE">KO</a>)</li>
<li>PepsiCo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pep#NASDAQ">PEP</a>)</li>
<li>Constellation Brands, Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/stz#NYSE">STZ</a>)</li>
</ul>
Food Products: +8.76%
<ul>
<li>Albertsons Companies Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aci#NYSE">ACI</a>)</li>
<li>SpartanNash Co (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sptn#NASDAQ">SPTN</a>)</li>
<li>Andersons Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ande#NASDAQ">ANDE</a>)</li>
</ul>
Tobacco: +9.27
<ul>
<li>Altria Group Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mo#NYSE">MO</a>)</li>
<li>British American Tobacco PLC (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bti#NYSE">BTI</a>)</li>
<li>Vector Group Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vgr#NYSE">VGR</a>)</li>
</ul>
Utilities: 
Electric Utilities: -1.71%
<ul>
<li>NRG Energy Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nrg#NYSE">NRG</a>)</li>
<li>DTE Energy Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dte#NYSE">DTE</a>)</li>
<li>OGE Energy Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/oge#NYSE">OGE</a>)</li>
</ul>
Multi-Utilities: +9.05%
<ul>
<li>PG&amp;E Corporation&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pcg#NYSE">PCG</a>)</li>
<li>Black Hills&nbsp;Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bkh#NYSE">BKH</a>)</li>
<li>Exelon Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exc#NASDAQ">EXC</a>)</li>
</ul>
Independent Power and Renewable Energy: -13.83%
<ul>
<li>Clearway Energy Inc Class A (NYSE:<a href="https://www.google.com/finance/quote/CWEN.A:NYSE"> CWEN.A</a>)</li>
<li>NextEra Energy Inc&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nee#NYSE">NEE</a>)</li>
<li>First Solar, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fslr#NASDAQ">FSLR</a>)</li>
</ul>
Health Care: 
Providers &amp; Services: +1.23%
<ul>
<li>National HealthCare Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nhc#NYSE">NHC</a>)</li>
<li>Davita Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>)</li>
<li>Alignment Healthcare Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alhc#NASDAQ">ALHC</a>)</li>
</ul>
Health Care Tech: +1.22%
<ul>
<li>Sophia Genetics SA (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/soph#NASDAQ">SOPH</a>)</li>
<li>Computer Programs &amp; Systems, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cpsi#NASDAQ">CPSI</a>)</li>
<li>HealthStream, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hstm#NASDAQ">HSTM</a>)</li>
</ul>
Pharmaceuticals: -0.55%
<ul>
<li>Viatris Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtrs#NASDAQ">VTRS</a>)</li>
<li>Regencell Bioscience Holdings Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rgc#NASDAQ">RGC</a>)</li>
<li>Prestige Consumer Healthcare Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pbh#NYSE">PBH</a>)</li>
</ul>
Photo:&nbsp;<a href="https://pixabay.com/users/theinvestorpost-19152356/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=5771541">TheInvestorPost</a>&nbsp;from&nbsp;Pixabay&nbsp;

ALHC

ANDE

CPSI

FSLR

SOPH

SPTN

VTRS

27 Recession-Resistant Stocks To Look At Now

National Healthcare (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NHC#AMEX">NHC</a>) reported quarterly earnings of $0.91 per share. This is a 15.74 percent decrease over earnings of $1.08 per share from the same period last year. The company reported $278.98 million in sales this quarter. This is a 11.16 percent increase over sales of $250.97 million the same period last year.

National Healthcare Q1 Adj. EPS $0.91 Down From $1.08 YoY, Sales $278.98M Up From $250.97M YoY

The stocks with the most extreme upside in 2Q - Piper Sandler

The stocks with the most extreme upside in Q2 - Piper Sandler

National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals.

Chart Of The Day: National HealthCare - Skilled Nursing Facilities

National Healthcare (NHC) has provided an announcement. Ernest G. Burgess, III, a director of NHC since 1997, will be retiring from the board on Ju...

National Healthcare Director Burgess Announces Retirement

McKesson (MCK) reported consistent revenue growth and solid profit margins in the last reported quarter, supported by robust demand for pharmaceuticals and medical supplies and efficient cost management. With nearly 25% year-to-date gains, should you invest in this healthcare stock? Read on to learn more… The medical industry contributes significantly to the economy by offering necessary products and services that advance people's health and well-being. The sector has seen notable changes in recent years because of significant technological developments, increased awareness of preventive care, and other biotechnological discoveries and innovations.
Demand for medical services will likely remain high due to an aging population, the growing frequency of rare and chronic illnesses, and enhanced health awareness. The global healthcare services market is expected to grow from $8.35 trillion in 2023 to $8.96 trillion in 2024 at a <a href="https://www.researchandmarkets.com/reports/5781185/healthcare-services-global-market-report">CAGR of 7.4%</a>. The market is projected to reach $10.91 trillion by 2028, expanding at a 5% CAGR.
With a $373.69 billion market cap, McKesson Corporation (<a href="https://stocknews.com/stock/MCK/">MCK</a>) specializes in the distribution of pharmaceuticals and medical supplies. It operates through four segments: U.S. Pharmaceutical; Prescription Technology Solutions (RxTS); Medical-Surgical Solutions; and International.
McKesson maintains a solid position in the healthcare sector, fueled by its broad range of products and services, extensive distribution network, and solid customer base. The company ended fiscal 2024 on a solid note, with full-year revenues of $309 billion, up 12% year-over-year. Its adjusted EPS for the year rose 6% year-over-year to $27.44.
Highlighting solid fourth-quarter performance, Brian Tyler, CEO of MCK, said, "The results underscore the execution against our company priorities, differentiated capabilities within the oncology and biopharma services platforms, and the sustained strength of our core distribution businesses. We continue to leverage the breadth and depth of our assets, delivering meaningful outcomes for our customers, partners, patients, and communities."
"Looking ahead to fiscal 2025, we are well-positioned to further expand on the extensive range of our assets and capabilities, execute against our strategic initiatives, foster sustainable growth, and create long-term value for all stakeholders," added Tyler.
For the fiscal year 2025, the company expects adjusted EPS to be $31.25 to $32.05, indicating a 14% to 17% growth compared to the previous year.
Shares of MCK have gained 18.4% over the past six months and 25% year-to-date to close the last trading session at $578.26.
Let's look at factors that could influence MCK's performance in the upcoming months.
Robust Financial Performance
For the fourth quarter that ended March 31, 2024, MCK's revenue increased 10.8% year-over-year to $76.36 billion. Revenue from the U.S. Pharmaceutical segment was $68.79 billion, up 12% year-over-year increase, primarily driven by higher prescription volumes, including increased volumes from specialty products, retail national account customers, and GLP-1 medications.
Also, revenue from the Medical-Surgical Solutions segment was $2.83 billion, up 6% from the year-ago value. MCK's <a href="https://www.investopedia.com/terms/g/grossprofit.asp#:~:text=Gross%20profit%20is%20the%20income,have%20been%20removed%20from%20revenue.">gross profit</a> grew 16.9% year-over-year to $3.59 billion. Its operating income came in at $1.22 billion, an increase of 24.1% year-over-year. The company reported adjusted earnings of $813 million, or $6.18 per share, respectively.
Favorable Analyst Expectations
Analysts expect MCK's revenue and EPS for the second quarter (ending September 2024) to grow 18.5% and 23.6% year-over-year to $91.49 billion and $7.70, respectively. Moreover, the company topped consensus revenue and EPS estimates in three of the trailing four quarters.
For the fiscal year ending March 2025, Street expects MCK's revenue and EPS to grow 16.9% and 15.6% from the prior year to $361.26 billion and $31.73, respectively. In addition, the company's revenue and EPS for the fiscal year 2026 are expected to increase 8.2% and 12.9% year-over-year to $390.83 billion and $35.83, respectively.
Impressive Historical Growth
Over the past five years, MCK's revenue has grown at a CAGR of 7.6%. The company's levered free cash flow has increased at a CAGR of 8% over the same period, and its EBITDA has improved at a 4.7% CAGR. Furthermore, the company's net income and EPS have increased at CAGRs of 145% and 164.4%, respectively, over the same time frame.
Attractive Valuation
In terms of forward non-GAAP P/E, MCK is trading at 18.21x, 7% lower than the industry average of 19.58x. The stock's forward EV/Sales multiple of 0.22 is 93.9% lower than the industry average of 3.57. Likewise, its forward EV/EBITDA of 13.23x is 1% lower than the industry average of 13.36x.
Additionally, the stock's forward Price/Sales multiple of 0.21 is 94.6% lower than the industry average of 3.85. Its forward Price/Cash Flow of 15x is 4.7% lower than the industry average of 15.75x.
POWR Ratings Reflect Promise
MCK's sound fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to Buy in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. MCK has a B grade for Value, consitent with its lower-than-industry valuation. The stock also has a B grade for Stability, justified by its 24-month beta of 0.22.
Within the <a href="https://stocknews.com/category/medical-services/">Medical - Services</a> industry, MCK is ranked #4 out of 63 stocks.
Beyond what I have stated above, we have also given MCK grades for Growth, Quality, Sentiment, and Momentum. Get all MCK ratings <a href="https://stocknews.com/stock/MCK/">here</a>.
Bottom Line
MCK plays a crucial role in the healthcare industry by ensuring the reliable distribution of essential medical products and solutions. Its solid customer base includes retail pharmacies, hospital networks, pharmaceutical manufacturers, and health systems. McKesson consistently reports robust revenue and earnings, driven by its vital role in the healthcare supply chain.
Given its solid financials, lower valuation, and promising growth prospects, investing in MCK would be wise now for potential gains.
How Does McKesson Corporation (MCK) Stack Up Against Its Peers?
While MCK has an overall POWR Rating of B, investors could also check out these other stocks within the <a href="https://stocknews.com/category/medical-services/">Medical - Services</a> industry with B (Buy) ratings: HealthStream, Inc. (<a href="https://stocknews.com/stock/HSTM/">HSTM</a>), AmerisourceBergen Corp. (<a href="https://stocknews.com/stock/ABC/">ABC</a>), and National HealthCare Corporation (<a href="https://stocknews.com/stock/NHC/">NHC</a>).
To explore more A and B-rated healthcare stocks, <a href="https://stocknews.com/category/medical-services/">click here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a> 

<hr />
MCK shares were unchanged in premarket trading Tuesday. Year-to-date, MCK has gained 25.32%, versus a 19.09% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Mangeet Kaur Bouns</h2> <img src='https:/wp-content/uploads/2022/01/Mangeet-Kaur-Bouns_Image-4.jpg' style="float:left; padding:5px;width:125px;">Mangeet's keen interest in the stock market led her to become an investment researcher and financial journalist. Using her fundamental approach to analyzing stocks, Mangeet's looks to help retail investors understand the underlying factors before making investment decisions.<a href="https://stocknews.com/authors/?author=mangeet-kaurbouns">More...</a>The post <a href=https://stocknews.com/news/mck-abc-nhc-hstm-with-25-ytd-gains-is-mckesson-a-smart-investment-now/>With 25% YTD Gains, Is McKesson a Smart Investment Now?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

With 25% YTD Gains, Is McKesson a Smart Investment Now?

As the need for high-quality and dependable pet insurance solutions becomes more acute, Trupanion (TRUP), a prominent pet insurance provider, is well-positioned to build ongoing momentum in this expanding market. However, with analysts forecasting a loss per share through 2024 and 2025, is TRUP a good bet? Read on to find out… Trupanion, Inc. (<a href="https://stocknews.com/stock/TRUP/">TRUP</a>) is a provider of specialty insurance products that primarily generates revenue through the sale of pet insurance, especially for cats and dogs. The company's medical plan covers most veterinary costs for accident and illness claims with no payout limitations.
With their unique direct payment system and round-the-clock pre-approval services, Trupanion makes it easier for pet owners to manage costs and care for their furry friends. While they don't offer wellness plans, their additional coverage options, like recovery care and pet owner assistance, provide flexible choices for pet lovers.
As the company prepares to release its second-quarter earnings report <a href="https://investors.trupanion.com/news/Press-Releases/news-details/2024/Trupanion-Inc.-Announces-Second-Quarter-2024-Earnings-Release-and-Conference-Call/default.aspx">on August 8</a>, 2024, analysts expect a 14.3% year-over-year revenue increase to $309.34 million. On the contrary, TRUP's loss per share is forecasted to sit at $0.18. Trupanion has consistently exceeded revenue and <a href="https://www.investopedia.com/terms/e/eps.asp">EPS</a> estimates in each of the trailing four quarters, including the first quarter.
In the first quarter of 2024, the company recorded $306.12 million in revenue, exceeding consensus expectations of $300.52 million and marking a 19% year-over-year increase. The company's EPS of negative $0.16 also beat expectations by $0.04.
Shares of TRUP have gained 64.8% in the past nine months and 21.1% over the past month to close the last trading session at $34.38.
Let's look at factors that could influence TRUP's performance in the upcoming months.
Recent Development
On June 12, the company announced a strategic <a href="https://investors.trupanion.com/news/Press-Releases/news-details/2024/Boehringer-Ingelheim--Trupanion-Announce-Exclusive-Collaboration-to-Increase-Access-to-Pet-Care/default.aspx">collaboration with Boehringer Ingelheim</a> to provide pets and their families with increased access to high-quality healthcare and enhanced disease treatment and protection.
The collaboration focuses on early detection of risk factors for common pet conditions, continuous veterinarian and consumer education, product extensions, promotions, and peer-reviewed publications.
Strong Financial Performance
For the fiscal first quarter that ended March 31, 2024, TRUP's revenues increased 19.4% year-over-year to $306.12 million. The total number of enrolled pets (including those from other business segments) for the quarter was 1,708,017, reflecting a 6% uptick from the previous year. Also, its subscription-enrolled pets grew by 11% year-over-year to 1,006,168.
The company's non-GAAP operating income rose 37.2% from the year-ago value to $21.31 million, while its adjusted EBITDA stood at $4.84 million versus an adjusted EBITDA loss of $4.87 million. In addition, its cash inflow from operating activities amounted to $2.43 million compared to an outflow of $6.86 million in the year-ago quarter.
Mixed Analyst Expectations
Analysts expect TRUP's revenue for the third quarter (ending September 2024) to increase 11.3% year-over-year to $318.26 million. However, the company is expected to post a loss per share of $0.06 in the ongoing quarter.
Similarly, for the fiscal year ending December 2024, TRUP's revenue is expected to grow 13.7% from the prior year to $1.26 billion and increase by 8.1% year-over-year in 2025.  On the other hand, the company's EPS is forecasted to remain negative at $0.39 for 2024 and $0.05 for 2025.
Dimmed Profitability
TRUP's trailing-12-month gross profit margin of 18.59% is 69.1% lower than the industry average of 60.07%. Similarly, the stock's trailing-12-month levered FCF margin of 0.23% is 98.7% lower than the industry average of 17.60%.
Additionally, TRUP's trailing-12-month ROCE and ROTA of negative 8.95% and negative 3.39% unfavorably compare to their respective industry averages of 10.57% and 1.06%. Also, the stock's net income margin is negative at 2.31% compared to the 22.93% industry average.
Mixed Valuation
In terms of forward EV/Sales, TRUP is trading at 1.13x, which is 64.4% lower than the industry average of 3.18x. Likewise, the stock's forward Price/Sales multiple of 1.15 is 60.2% below the industry average of 2.88.  
However, TRUP's forward EV/EBITDA of 43.19x is 330.1% higher than the industry average of 10.04x. Also, its forward Price/Book ratio of 4.66x compares with the industry average of 1.22x.
POWR Ratings Exhibit Mixed Prospects
TRUP's stance is apparent in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of C, which translates to Neutral in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. TRUP is trading above its 50-day moving average of $29.69 and the 200-day moving average of $27.37, justifying its A grade for Momentum.
Yet, the stock received a C for Sentiment, corresponding with its mixed analysts' estimates. Also, with a 24-month beta of 2.34, the stock has earned a grade of D for Stability.
TRUP is ranked #41 out of 63 stocks in the <a href="https://stocknews.com/category/medical-services/">Medical - Services</a> industry. <a href="https://stocknews.com/stock/TRUP/">Click here</a> to access TRUP's Growth, Value, and Quality ratings.
Bottom Line
The pet insurance market is booming, with North Americans spending over $62 billion annually on their furry friends. Yet, only a tiny fraction (less than 5%) of these pets are insured, leaving a huge growth opportunity for companies like Trupanion. By 2033, the global pet insurance market is estimated to reach $38.3 billion, growing at <a href="https://www.marketwatch.com/press-release/pet-insurance-market-to-reach-38-3-billion-globally-by-2033-at-14-5-cagr-allied-market-research-7588447c">a CAGR of 14.5%</a> from 2024 to 2033.
As we anticipate TRUP's second-quarter results, analysts foresee its earnings per share to remain negative throughout the fiscal years 2024 and 2025, alongside solid revenue growth. Given TRUP's mixed valuation, weak profitability metrics, and heightened volatility, it could be wise to wait for a better entry point in this stock now.
How Does Trupanion, Inc. (TRUP) Stack Up Against Its Peers?
While TRUP has an overall grade of C, equating to a Neutral rating, you may check out these A (Strong Buy) rated stocks within the <a href="https://stocknews.com/category/medical-services/">Medical - Services</a> industry: Fresenius Medical Care AG (<a href="https://stocknews.com/stock/FMS/">FMS</a>), National HealthCare Corporation (<a href="https://stocknews.com/stock/NHC/">NHC</a>), and McKesson Corporation (<a href="https://stocknews.com/stock/MCK/">MCK</a>). To explore more Medical - Services, <a href="https://stocknews.com/category/medical-services/">click here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
TRUP shares were trading at $35.61 per share on Friday afternoon, up $1.23 (+3.58%). Year-to-date, TRUP has gained 16.72%, versus a 15.84% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/trup-fms-nhc-mck-is-trupanion-a-good-bet-on-pet-insurance/>Is Trupanion a Good Bet on Pet Insurance?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Trupanion a Good Bet on Pet Insurance?

National Healthcare (NHC) has provided an update. National HealthCare Corporation (NHC) secured a $200 million senior credit facility from Bank of ...

National Healthcare Expands Portfolio with Strategic Acquisitions

National Healthcare declares $0.61 dividend

National Healthcare Non-GAAP EPS of $1.00, revenue of $300.65M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
National Healthcare (NYSEMKT:<a href="https://investorplace.com/stock-quotes/nhc-stock-quote/">NHC</a>) just reported results for the second quarter of 2024.<ul><li>National Healthcare reported earnings per share of $1.00.</li><li>The company reported revenue of $300.66 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/nhc-stock-earnings-national-healthcare-for-q2-of-2024/">NHC Stock Earnings: National Healthcare Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NHC Stock Earnings: National Healthcare Reported Results for Q2 2024

ACIW

ANET

GDDY

HWKN

MLKN

PAHC

QCOM

QNST

SPTM

STEP

TRUP

Press Releases

Land & Buildings Issues Letter to Shareholders of National Health Investors Announcing its Intention to Vote Against Two Directors at 2024 Annual Meeting

Land & Buildings Comments on Half Measures Announced by National Health Investors in Advance of Upcoming Annual Meeting

NHC Announces 3.4% Increase in Common Dividend

NHC Reports First Quarter 2024 Earnings

NHC to Acquire White Oak Senior Living Portfolio

NHC Completes Acquisition of White Oak Senior Living Portfolio

NHC Announces Common Dividend

NHC Reports Second Quarter 2024 Earnings

Kaskela Law LLC Announces Stockholder Investigation of National HealthCare Corporation (NYSE: NHC) and Encourages Investors to Contact the Firm

Bausch Health Announces Third Quarter 2024 Results

TSX:BHC

Comments

National Healthcare

Notizie

Ultime notizie per National Healthcare (AMEX:NHC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO